Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 8, 2011, Pages 1404-1411

  Machado Neto, João Agostinho ^a   Favaro, Patricia ^a,b   Lazarini, Mariana ^a   Costa, Fernando Ferreira ^a   Olalla Saad, Sara T ^a   Traina, Fabiola ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Akt mTOR; BCR ABL; IRS1; K562 cell; MAPK; Proliferation

Indexed keywords

BCR ABL PROTEIN; IMATINIB; INSULIN RECEPTOR SUBSTRATE 1; LENTIVIRUS VECTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; S6 KINASE; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 79959369893     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.04.002     Document Type: Article

References (40)

1. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
2. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079-1082.
3. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 2001, 344:1038-1042.
4. O'Hare T., Eide C.A., Deininger M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110:2242-2249.
5. Shah N.P., Sawyers C.L. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003, 22:7389-7395.
6. Dearth R.K., Cui X., Kim H.J., Hadsell D.L., Lee A.V. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 2007, 6:705-713.
7. Taniguchi C.M., Emanuelli B., Kahn C.R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 2006, 7:85-96.
8. Shepherd P.R. Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues. Acta Physiol. Scand. 2005, 183:3-12.
9. Shepherd P.R., Withers D.J., Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem. J. 1998, 333(Pt 3):471-490.
10. Myers M.G., Wang L.M., Sun X.J., Zhang Y., Yenush L., Schlessinger J., Pierce J.H., White M.F. Role of IRS-1-GRB-2 complexes in insulin signaling. Mol. Cell. Biol. 1994, 14:3577-3587.
11. Skolnik E.Y., Batzer A., Li N., Lee C.H., Lowenstein E., Mohammadi M., Margolis B., Schlessinger J. The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 1993, 260:1953-1955.
12. Torii S., Yamamoto T., Tsuchiya Y., Nishida E. ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci. 2006, 97:697-702.
13. Ueno H., Kondo E., Yamamoto-Honda R., Tobe K., Nakamoto T., Sasaki K., Mitani K., Furusaka A., Tanaka T., Tsujimoto Y., Kadowaki T., Hirai H. Association of insulin receptor substrate proteins with Bcl-2 and their effects on its phosphorylation and antiapoptotic function. Mol. Biol. Cell 2000, 11:735-746.
14. D'Ambrosio C., Keller S.R., Morrione A., Lienhard G.E., Baserga R., Surmacz E. Transforming potential of the insulin receptor substrate 1. Cell Growth Differ. 1995, 6:557-562.
15. Ito T., Sasaki Y., Wands J.R. Overexpression of human insulin receptor substrate 1 induces cellular transformation with activation of mitogen-activated protein kinases. Mol. Cell. Biol. 1996, 16:943-951.
16. Tanaka S., Ito T., Wands J.R. Neoplastic transformation induced by insulin receptor substrate-1 overexpression requires an interaction with both Grb2 and Syp signaling molecules. J. Biol. Chem. 1996, 271:14610-14616.
17. Traina F., Carvalheira J.B., Saad M.J., Costa F.F., Saad S.T. BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells. FEBS Lett. 2003, 535:17-22.
18. Juric D., Lacayo N.J., Ramsey M.C., Racevskis J., Wiernik P.H., Rowe J.M., Goldstone A.H., O'Dwyer P.J., Paietta E., Sikic B.I. Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J. Clin. Oncol. 2007, 25:1341-1349.
19. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
20. Araki E., Lipes M.A., Patti M.E., Bruning J.C., Haag B., Johnson R.S., Kahn C.R. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994, 372:186-190.
21. Tamemoto H., Kadowaki T., Tobe K., Yagi T., Sakura H., Hayakawa T., Terauchi Y., Ueki K., Kaburagi Y., Satoh S., et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994, 372:182-186.
22. Dearth R.K., Cui X., Kim H.J., Kuiatse I., Lawrence N.A., Zhang X., Divisova J., Britton O.L., Mohsin S., Allred D.C., Hadsell D.L., Lee A.V. Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol. Cell. Biol. 2006, 26:9302-9314.
23. Cristofanelli B., Valentinis B., Soddu S., Rizzo M.G., Marchetti A., Bossi G., Morena A.R., Dews M., Baserga R., Sacchi A. Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras. Oncogene 2000, 19:3245-3255.
24. Nolan M.K., Jankowska L., Prisco M., Xu S., Guvakova M.A., Surmacz E. Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells. Int. J. Cancer 1997, 72:828-834.
25. Oliveira J.C., Souza K.K., Dias M.M., Faria M.C., Ropelle E.R., Flores M.B., Ueno M., Velloso L.A., Saad S.T., Saad M.J., Carvalheira J.B. Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts. J. Cancer Res. Clin. Oncol. 2008, 134:833-839.
26. Taouis M., Dupont J., Gillet A., Derouet M., Simon J. Insulin receptor substrate 1 antisense expression in an hepatoma cell line reduces cell proliferation and induces overexpression of the Src homology 2 domain and collagen protein (SHC). Mol. Cell. Endocrinol. 1998, 137:177-186.
27. Tanaka S., Mohr L., Schmidt E.V., Sugimachi K., Wands J.R. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology 1997, 26:598-604.
28. Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, Park S, Green AS, Ifrah N, Dreyfus F, Mayeux P, Lacombe C and Bouscary D. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 95:415-23.
29. Cobb M.H. MAP kinase pathways. Prog. Biophys. Mol. Biol. 1999, 71:479-500.
30. Grammer T.C., Cheatham L., Chou M.M., Blenis J. The p70S6K signalling pathway: a novel signalling system involved in growth regulation. Cancer Surv. 1996, 27:271-292.
31. Ferrari S., Thomas G. S6 phosphorylation and the p70s6k/p85s6k. Crit. Rev. Biochem. Mol. Biol. 1994, 29:385-413.
32. de Groot R.P., Ballou L.M., Sassone-Corsi P. Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression. Cell 1994, 79:81-91.
33. Shah S.A., Potter M.W., Ricciardi R., Perugini R.A., Callery M.P. FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation. J. Surg. Res. 2001, 97:123-130.
34. Skeen J.E., Bhaskar P.T., Chen C.C., Chen W.S., Peng X.D., Nogueira V., Hahn-Windgassen A., Kiyokawa H., Hay N. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 2006, 10:269-280.
35. Min Y.H., Eom J.I., Cheong J.W., Maeng H.O., Kim J.Y., Jeung H.K., Lee S.T., Lee M.H., Hahn J.S., Ko Y.W. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 2003, 17:995-997.
36. Sujobert P., Bardet V., Cornillet-Lefebvre P., Hayflick J.S., Prie N., Verdier F., Vanhaesebroeck B., Muller O., Pesce F., Ifrah N., Hunault-Berger M., Berthou C., Villemagne B., Jourdan E., Audhuy B., Solary E., Witz B., Harousseau J.L., Himberlin C., Lamy T., Lioure B., Cahn J.Y., Dreyfus F., Mayeux P., Lacombe C., Bouscary D. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005, 106:1063-1066.
37. Billottet C., Grandage V.L., Gale R.E., Quattropani A., Rommel C., Vanhaesebroeck B., Khwaja A. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006, 25:6648-6659.
38. Chung CH, Pohlmann PR, Rothenberg ML, Burkey BB, Parker J, Palka K, Aulino J, Puzanov I and Murphy B. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head Neck.
39. Tarn C., Rink L., Merkel E., Flieder D., Pathak H., Koumbi D., Testa J.R., Eisenberg B., von Mehren M., Godwin A.K. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 2008, 105:8387-8392.
40. Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A and de Bono JS. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 103:332-9.